静脉甲泼尼龙在巨细胞动脉炎中的应用:一项基于人群的研究
该回顾性研究纳入2004年至2019年诊断的419例活检确诊巨细胞动脉炎患者,比较初始接受静脉甲泼尼龙(IVMP)与仅口服糖皮质激素(OGC)患者的临床特征、视力变化、共病发生及死亡情况。结果显示IVMP组视力改善无统计学意义(OR 1.19,95%CI 0.35-4.01),但一年内新诊断糖尿病风险升高(OR 2.59,95%CI 1.19-5.63),调整三个月累积OGC剂量后仍升高(调整OR 3.30,95%CI 1.29-8.43),两组生存无差异。
要点
- IVMP组就诊时炎症反应低于OGC组。
- IVMP组视力改善无统计学意义(OR 1.19,95%CI 0.35-4.01)。
- IVMP组一年内新诊断糖尿病风险升高(OR 2.59,95%CI 1.19-5.63)。
核心结论
- 本研究未发现支持IVMP改善视力或生存获益的证据,IVMP可能增加巨细胞动脉炎诊断后一年内的糖尿病风险,需进一步研究评估IVMP在巨细胞动脉炎中的价值。
研究设计与样本
- 回顾性研究纳入2004年至2019年诊断的419例活检确诊巨细胞动脉炎患者(69%女性),比较初始接受IVMP(111例)与仅接受OGC(308例)患者的临床和实验室特征及累积GC剂量,并分析视力变化、共病发生和死亡。
主要发现
- 111例初始接受IVMP治疗,其中104例(94%)起病时有视觉表现;90例(21.5%)起病时有眼科医生证实的视觉受累。
- 与OGC相比,接受IVMP的患者就诊时炎症反应较低。
- IVMP组视力改善有趋势但无统计学意义(OR 1.19,95%CI 0.35-4.01)。
- IVMP组巨细胞动脉炎诊断后一年内新诊断糖尿病风险升高(OR 2.59,95%CI 1.19-5.63),调整三个月累积OGC剂量后仍升高(调整OR 3.30,95%CI 1.29-8.43)。
- 两组生存无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine clinical characteristics, outcome and occurrence of comorbidities in patients with biopsy-confirmed giant cell arteritis (GCA) treated with intravenous methylprednisolone (IVMP) vs those receiving oral glucocorticoids (OGC) only. METHODS: A retrospective study included patients with GCA diagnosed from 2004 through 2019. Clinical and laboratory characteristics, and cumulative GC dose were compared in patients receiving IVMP vs OGCs. Changes in visual acuity (VA), occurrence of comorbidities after GCA diagnosis, and mortality were analysed. RESULTS: A total of 419 patients (69% female) were included. In total, 111 patients were initially treated with IVMP, 104 (94%) of whom showed visual manifestations at onset and 308 received OGCs only. Ninety patients (21.5%) exhibited visual involvement at onset, verified by an ophthalmologist. Compared with OGC, patients receiving IVMP exhibited lower inflammatory response at presentation. There was a tendency for improvement in VA with the use of IVMP, but the results were not statistically significant (OR 1.19, 95% CI 0.35-4.01). Patients treated with IVMP had a higher risk of newly diagnosed diabetes mellitus within a year of GCA diagnosis (OR 2.59, 95% CI 1.19-5.63). This risk remained elevated after adjusting for cumulative OGC dose at three months (adjusted OR 3.30, 95% CI 1.29-8.43). There was no difference in survival between treatment groups. CONCLUSIONS: Our study found no evidence supporting any benefit of using IVMP in improving VA or survival. IVMP may increase diabetes risk within a year of GCA diagnosis. Further studies are needed to evaluate the value of IVMP in GCA.
引用
- Henningson H, Hammar B, Mohammad AJ, et al. The use of intravenous methylprednisolone in giant cell arteritis: a population-based study. Rheumatology (Oxford). 2025. PMID: 39190002. doi:10.1093/rheumatology/keae459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。